drugset / Trial / NCT03872232

Evaluating the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and Telmisartan

NCT03872232

Phase 3 Completed 180 enrolled Addpharma Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of co-administrated Rosuvastatin/Ezetimibe and Telmisartan in patients with primary hypercholesterolemia and essential hypertension.

Timeline

Start
2019-02-26
Primary completion
2020-08-12
Completion
2020-08-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Ezetimibe Unknown Oral
Subject Rosuvastatin Small molecule Oral
Subject Telmisartan Other / unclassified Oral